
Novo’s Capital Markets Day fails to halt Eli Lilly’s expanding obesity lead
Novo Nordisk’s recent strategy presentation failed to reassure investors, as Eli Lilly continues to widen its market share advantage in obesity treatments. While Novo outlined a broad pipeline to replace its flagship drugs, Lilly’s commercial strength and new products are driving a significant shift in market dominance.






